These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 27502552)
1. Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes. Horbach SE; Jolink F; van der Horst CM Dermatol Ther; 2016 Nov; 29(6):466-469. PubMed ID: 27502552 [TBL] [Abstract][Full Text] [Related]
2. Update on classification and diagnosis of vascular malformations. McCuaig CC Curr Opin Pediatr; 2017 Aug; 29(4):448-454. PubMed ID: 28654575 [TBL] [Abstract][Full Text] [Related]
9. Combined capillary-venous-lymphatic malformations without overgrowth in patients with Klippel-Trénaunay syndrome. Brandigi E; Torino G; Messina M; Molinaro F; Mazzei O; Matucci T; López Gutiérrez JC J Vasc Surg Venous Lymphat Disord; 2018 Mar; 6(2):230-236. PubMed ID: 29233587 [TBL] [Abstract][Full Text] [Related]
10. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. Danial C; Tichy AL; Tariq U; Swetman GL; Khuu P; Leung TH; Benjamin L; Teng J; Vasanawala SS; Lane AT J Am Acad Dermatol; 2014 Jun; 70(6):1050-7. PubMed ID: 24656411 [TBL] [Abstract][Full Text] [Related]
11. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum. Yeung KS; Ip JJ; Chow CP; Kuong EY; Tam PK; Chan GC; Chung BH Am J Med Genet A; 2017 Apr; 173(4):978-984. PubMed ID: 28328134 [TBL] [Abstract][Full Text] [Related]
12. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309 [TBL] [Abstract][Full Text] [Related]
13. [New nosological and therapeutic perspectives in syndromic vascular malformations with a vein-lymphatic component]. Henneton P; Mestre S; Nou M; Quere I Rev Med Interne; 2018 Oct; 39(10):800-804. PubMed ID: 29627129 [TBL] [Abstract][Full Text] [Related]
14. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230 [TBL] [Abstract][Full Text] [Related]
19. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes. Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986 [TBL] [Abstract][Full Text] [Related]
20. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]